CMS Revisits Part D "Protected Classes" Rule
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS drops proposal for a panel of outside experts, but still wants a "data-driven" process for selecting protected drug classes.
You may also be interested in...
CMS Creates Regulatory Pathway For Altering Protected Classes Under Part D
Potential changes to current list of six protected classes will be reviewed by “expert panel” and subject to public rulemaking process.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.